SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Three Months ended September 30, 1999 Commission File No. 0-6436
BLOCK DRUG COMPANY, INC.
(Exact name of registrant as specified in its charter)
New Jersey 22-1375645
(State or other (I.R.S. Employer
Jurisdiction of Identification No.)
incorporation or
organization)
257 Cornelison Avenue, Jersey City, New Jersey 07302-9988
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (201) 434-3000
Indicate by check mark whether Registrant (1) has filed all Commission reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter periods that the
Registrant is required to file such reports) and (2) has been subject to such
reports) and (2) has been subject to such filing requirements for the past 90
days.
Yes X No
Indicate the number of shares outstanding of each of the issuer's classes of
Common Stock, as of the close of the period covered by this report.
(Class) (Outstanding at September 30, 1999)
Common Stock - Class A 14,474,122
Common Stock - Class B 8,418,808
<PAGE>1
BLOCK DRUG COMPANY, INC.
INDEX TO FORM 10-Q
SEPTEMBER 30, 1999
Part I. Financial Information - Unaudited Page No.
Consolidated Balance Sheets - September 30, 1999 and 3
March 31, 1999
Consolidated Statements of Income for the three and six 4
months ended September 30, 1999 and 1998
Consolidated Statements of Comprehensive 5
Income for the three and six months ended
September 30, 1999 and 1998.
Condensed Consolidated Statements of Cash Flows 6
for the six months ended September 30, 1999 and 1998
Notes to Consolidated Financial Statements 7-10
Management's Discussion and Analysis of 10-16
Operating Results and Financial Condition
Part II. Other Information 17
<PAGE>2
<TABLE>
BLOCK DRUG COMPANY, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
<CAPTION>
(Unaudited)
<S> <C> <C>
ASSETS 09/30/99 03/31/99
------------- ------------
Current Assets:
Cash and cash equivalents........................................... $ 61,866,000 $ 48,363,000
Marketable securities, at market.................................... 21,763,000 29,994,000
Accounts receivable, less allowances of $4,670,000 (9/30/99) and
$4,750,000 (3/31/99).............................................. 150,888,000 153,470,000
Inventory .......................................................... 147,373,000 135,947,000
Other current assets................................................ 47,482,000 41,867,000
------------- -------------
Total current Assets............................................ 429,372,000 409,641,000
------------- -------------
Property, plant and equipment, less accumulated
depreciation of $138,491,000 (9/30/99)
and $135,261,000 (3/31/99)........................................ 244,675,000 252,270,000
Long term securities, at market..................................... 256,109,000 257,082,000
Goodwill and other intangible assets - net of amortization.......... 262,099,000 239,818,000
Other assets........................................................ 9,524,000 7,952,000
------------- -------------
Total Assets.................................................... $1,201,779,000 $1,166,763,000
============== ==============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Notes and bonds payable............................................. $180,215,000 $143,740,000
Accounts payable & accrued expenses................................. 189,884,000 185,270,000
Income taxes payable................................................ 16,379,000 13,532,000
Dividends payable................................................... 5,527,000 5,521,000
------------- -------------
Total Current Liabilities....................................... 392,005,000 348,063,000
------------- -------------
Notes and bonds payable............................................. 104,450,000 107,012,000
Deferred compensation and other liabilities......................... 19,644,000 19,648,000
Deferred income taxes............................................... 8,451,000 8,155,000
------------- -------------
Total Liabilities............................................... 524,550,000 482,878,000
------------- -------------
Shareholders' Equity:
Class A common stock, non-voting, par
value $.10-20,000,000 shares authorized,
14,474,000 (9/30/99) and 14,456,000
(3/31/99) shares issued and outstanding........................... 1,447,000 1,445,000
Class B common stock par value $.10-
40,000,000 shares authorized, 8,419,000
shares issued and outstanding................................... 842,000 842,000
Capital in excess of par value...................................... 307,015,000 306,433,000
Retained earnings................................................... 400,923,000 384,952,000
Cumulative other comprehensive (loss)............................... (32,998,000) (9,787,000)
------------- -------------
Total Shareholders' Equity........................................ 677,229,000 683,885,000
------------- -------------
Total Liabilities & Shareholder's Equity.......................... $1,201,779,000 $1,166,763,000
============== ==============
</TABLE>
See notes to consolidated financial statements.
<PAGE>3
BLOCK DRUG COMPANY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
<TABLE>
<CAPTION>
(UNAUDITED)
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------------------------- ---------------------------------
1999 1998 1999 1998
------------ ------------- ------------ -------------
<S> <C> <C> <C> <C>
Revenues:
Net sales................... $214,868,000 $204,063,000 $415,763,000 $393,510,000
Interest, dividends
and other income......... 7,077,000 5,165,000 13,695,000 18,384,000
------------ ------------ ------------ ------------
221,945,000 209,228,000 429,458,000 411,894,000
============ ============ ============ ============
Cost and expenses:
Cost of goods sold.......... 66,966,000 63,098,000 127,876,000 119,488,000
Selling, general and
administrative........... 133,059,000 125,924,000 258,121,000 252,478,000
Interest expense............ 3,585,000 3,296,000 6,842,000 6,824,000
------------ ------------ ------------ ------------
203,610,000 192,318,000 392,839,000 378,790,000
============ ============ ============ ============
Income before income taxes 18,335,000 16,910,000 36,619,000 33,104,000
Income taxes................ 4,457,000 4,116,000 9,594,000 8,375,000
------------ ------------ ------------ ------------
Net income.................. $13,878,000 $12,794,000 $27,025,000 $24,729,000
============ ============ ============ ============
Weighted average number of
shares outstanding....... 22,891,752 22,846,406(1) 22,886,770 22,840,585(1)
============ ============ ============ ============
Net income per share........ $ 0.61 $ 0.56(1) $ 1.18 $ 1.08(1)
(Basic and diluted)
Cash dividends per share
Class A common stock..... $ 0.3175 $ 0 .315 $ 0.635 $ 0.63
Class B common stock..... $ 0.110625 $ 0 .11 $ 0.22125 $ 0.22
</TABLE>
(1) Restated to reflect 3% stock dividend declared in November 1998.
See notes to consolidated financial statements.
<PAGE>4
BLOCK DRUG COMPANY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
<TABLE>
<CAPTION>
(UNAUDITED)
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
1999 1998 1999 1998
------------ ------------- ------------ -------------
<S> <C> <C> <C> <C>
Net income.................. $13,878,000 $12,794,000 $27,025,000 $24,729,000
Other comprehensive
income (loss):
Foreign currency
translation adjustment *. (4,200,000) 1,229,000 (19,550,000) (4,450,000)
Unrealized holding (losses)
gains on marketable
securities, net of taxes. (1,051,000) 2,162,000 (3,661,000) 2,318,000
------------ ------------ ------------ ------------
Other comprehensive
income (loss)............ (5,251,000) 3,391,000 (23,211,000) (2,132,000)
------------ ------------ ------------ ------------
Comprehensive income........ $ 8,627,000 $16,185,000 $ 3,814,000 $22,597,000
=========== ============ ============= ===========
</TABLE>
* The Company does not provide for U.S. income taxes on foreign currency
translation adjustments because it does not provide for such taxes on
undistributed earnings of foreign subsidiaries.
See notes to consolidated financial statements.
<PAGE>5
BLOCK DRUG COMPANY INC. & SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
(UNAUDITED)
SIX MONTHS ENDED
SEPTEMBER 30
1999 1998
------------ ------------
<S> <C> <C>
CASH FLOW FROM CONTINUING OPERATING ACTIVITIES......................... $ 36,541,000 $ 25,425,000
CASH FLOW FROM INVESTING ACTIVITIES:
Proceeds from Product divestiture................................... 19,000,000
Additions to Property, Plant and Equipment.......................... (17,293,000) (18,543,000)
Proceeds from Sales of Assets....................................... 1,343,000 31,790,000
Proceeds from Sales of Securities................................... 18,683,000 94,940,000
Purchase of Securities.............................................. (32,137,000) (95,805,000)
Decrease in Marketable Securities.................................. 18,098,000 5,148,000
Payments for Products Acquired...................................... (50,586,000) (24,915,000)
------------ -----------
Net Cash Used in Investing Activities.................................. (42,892,000) (7,385,000)
------------ -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Dividends paid to Shareholders...................................... (11,054,000) (10,620,000)
Proceeds from Issuance of notes payable............................. 50,000,000
(Decrease) increase in long-term debt............................... (2,660,000) -
Increase (decrease) in short-term debt.............................. 36,573,000 (67,790,000)
------------ -----------
Net Cash (Used in ) Provided by Financing Activities................... 22,859,000 (28,410,000)
------------ -----------
Effect of Exchange Rate changes on Cash and Cash equivalents........... (3,005,000) 1,167,000
------------ -----------
Increase (decrease) in Cash and Cash equivalents....................... 13,503,000 (9,203,000)
Cash and Cash equivalents Beginning of Period.......................... 48,363,000 37,320,000
------------ -----------
Cash and Cash equivalents End of Period................................ $61,866,000 $28,117,000
============ ===========
SUPPLEMENTAL CASH FLOW DATA:
Cash Paid during the Year:
Interest.......................................................... $ 6,819,000 $ 7,119,000
Income taxes...................................................... $10,743,000 $ 2,882,000
</TABLE>
See notes to consolidated financial statements.
<PAGE>6
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. The consolidated financial statements reflect all normal recurring
adjustments which, in management's opinion, are necessary for a fair
presentation of the results for interim periods.
The accompanying consolidated financial statements should be read in
conjunction with the financial statement disclosures contained in the
Company's 1999 Form 10-K.
2. Provision for certain expenses, including income taxes, media advertising,
and consumer promotions, are based on full year assumptions. Such expenses
are charged to operations in the year incurred and are included in the
accompanying consolidated financial statements in proportion with the
passage of time or with estimated annual sales or annual tax rates.
3. Inventories by major classes were as follows:
<TABLE>
<CAPTION>
September 30, 1999 March 31, 1999
(Unaudited)
<S> <C> <C>
Raw and packaging materials $ 42,931,000 $ 30,997,000
Finished goods 104,442,000 104,950,000
------------- ------------
$147,373,000 $135,947,000
============= ============
</TABLE>
4. Under the provisions of SFAS No. 130 "Reporting Comprehensive Income", the
Company has included a statement of Comprehensive Income in the
accompanying financial statements. Comprehensive income is comprised
primarily of net income, unrealized gain (loss) on marketable securities
and foreign currency translation adjustments.
5. In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivatives and
Hedging Activities," which establishes accounting and reporting standards
for derivative instruments, including certain derivative instruments
embedded in other contracts (collectively referred to as derivatives) and
for hedging activities. In June 1999, the FASB issued SFAS No. 137,
"Accounting For Derivatives and Hedging Activities - Deferral of the
Effective Date of SFAS No. 133," which makes SFAS No. 133 effective for all
fiscal quarters of fiscal years beginning after June 15, 2000. The Company
is currently evaluating the impact of the new statement on it's financial
position, results of operations and disclosures for fiscal 2002.
6. During the quarter the Company acquired Chlorhexamed, a medicated mouth
wash in Holland. In Latin America, the Company acquired Silidron and
Espasmo Silidron, two anti-gas medicines sold in Brazil. In Korea, the
Company acquired the balance of certain marketing rights to the Parodontax
brand toothpaste. The aggregate amount spent on these product acquisitions
was $50.6 million. Goodwill recorded in connection with these product
acquisitions amounted to $50.0 million.
7. During the six month period ended September 30, 1999, the Company increased
its net borrowings by $33.9 million primarily from lines of credit from
various banks bearing interest at variable rates.
<PAGE>7
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Cont'd)
8. During fiscal 1999, the Company adopted SFAS No. 131, "Disclosures about
Segments of an Enterprise and Related Information". SFAS 131 establishes
standards for the way public business enterprises report information about
operating segments in reports to shareholders. The adoption of SFAS 131 did
not affect results of operations or financial position but did affect the
disclosure of segment information. At the end of fiscal 1999 the segments
were divided into three geographic areas: United States; Europe, Africa,
Middle East, and Latin America, Canada, Asia/Pacific. During the current
period, the operations are divided into two geographic areas: Americas,
covering USA, Canada and Latin America, and International, covering Europe,
Asia/Pacific, Africa and Middle East. Prior year data has been restated
for comparability purposes.
<TABLE>
<CAPTION>
Six Months ended September 30,
1999 1998
(in thousands)
-------- --------
<S> <C> <C>
Net Sales
Americas $205,954 $202,576
International 209,809 190,934
--------- --------
Total consolidated sales $415,763 $393,510
========= ========
Operating Income:
Americas $ 28,633 $ 30,339
International 28,116 21,436
--------- ---------
56,749 51,775
General corporate expenses (20,130) (18,671)
---------- ----------
Consolidated income before
income taxes $ 36,619 $ 33,104
========== ==========
</TABLE>
9. In February 1997, the Company announced the consolidation of its
manufacturing operations by planning to close six of its twelve production
facilities in various parts of the world over a two year period. The
worldwide manufacturing restructuring and re-engineering program
resulted in a pre-tax charge of $72.5 million ($55.7 million net of tax),
or $2.60 per share after taxes in fiscal 1997, of which 8.7 million remains
as a current liability as of September 30, 1999.
<PAGE>8
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Cont'd)
The following table displays a rollforward of the liabilities for the
manufacturing restructuring from inception to September 30, 1999.
<TABLE>
<CAPTION>
(Dollars in Thousands)
Amount
Original Amounts Amount Amount Amount Utilized
Provision Utilized Remaining Utilized Remaining Utilized Reversed Ending for six Ending *
Fiscal in Fiscal Balance in Fiscal Balance in Fiscal in Fiscal Balance Months Balance
Type Cost 1997 1997 3-31-97 1998 Other 3-31-98 1999 1999 3-31-99 Fiscal 2000 9-30-99
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Employee $15,454(a) - $15,454 $7,516) ($3,300) $ 4,638 ($2,637) ($2,001) - - -
severance
and
related
costs
Plant 32,978(b) ($24,468) 8,510 - (8,510) - - - - - -
closing
and
related
asset
write-offs
Re-engineering 7,184(c) (7,184) - - - - - - - - -
Contractual
obligations
and other 16,834(d) (5,042) 11,792 (7,500) 11,110 15,402 (562) (5,640) $9,200 $ (500) $8,700
------- -------- ------ ------- ------ ------- -------- ------- ------ ------ ------
$72,450 ($36,694) $35,756 ($15,016) ($700) $20,040 ($3,199) ($7,641) $9,200 $ (500) $8,700
</TABLE>
*The balance at the end of the quarter is classified as a current liability.
(a) Represents severance costs for approximately 450 production employees
at six facilities. Estimates were based on calculations derived by
attorneys who considered the local labor laws at each location.
(b) Represents estimated impairment losses on land and buildings to be sold
($15 million)and machinery and equipment to be disposed ($14 million).
Also included is the estimate of site cleanup costs ($4 million).
Estimates were based principally on appraisals from third-party
appraisers.
(c) Principally represents consulting costs, as well as limited training
and maintenance costs, which were expensed during 1997.
(d) Represents consulting and legal fees and other costs.
As of September 30, 1999, the Company's remaining obligation of $8.7
million consists of its contractual obligation to produce a product for
another entity at a plant that is scheduled for closure.
Subsequent to the close of the quarter, the Company sold the remaining
manufacturing facility at a price that is approximately equal to the net
book value of the property. In connection with the sale, the Company will
be relieved of its contractual obligation described above but will incur
training costs and other expenses to move production equipment to an
unrelated party's facility. Management anticipates that this sale should
resolve all remaining contingencies associated with the restructuring
reserve.
10. Subsequent to the close of the quarter, in U.K., the Company acquired
Interdens a professional dental product. In Spain, the Company acquired
Marie Yvonne a depilatory brand. The aggregate amount spent on these
acquisitions was $4.2 million, the majority of which is considered
goodwill.
<PAGE>9
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Cont'd)
11. Legal Proceedings:
The company is involved in various routine ligation incidental to its
continuing and discontinued operations. While the significance of these
matters cannot be fully assessed at this time, management, on advice of
counsel, does not believe that any liability that may arise from these
proceedings will have a material adverse impact on the Company's
consolidated financial position, results of operations or liquidity.
BLOCK DRUG COMPANY, INC. & SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF OPERATING RESULTS AND FINANCIAL CONDITION
Operating Results:
Consolidated worldwide sales were $214.9 million in the second quarter
and $415.8 million for the first 6 months of fiscal year 2000, increases of 5.3%
and 5.7% respectively over the comparable prior year periods. In the first
quarter the company sold the Lava brand hand soap and during the fiscal year
ended March 31, 1999 the company had sold three of its household products
brands. Excluding the effects of the divestitures and the stronger US dollar,
consolidated sales were $220.2 million in the second quarter and $423.8 million
for the first six months of the year, increases of 11.2% and 11.4%, respectively
over the prior year periods.
Our operations are divided into two divisions: the Americas Division
covering markets in North and South America and the International Division,
covering Europe, Asia/Pacific, Africa and the Middle East.
Sales of $107.9 million for the Americas Division in the quarter were
flat with last year. Total US Division sales of $87.5 million were up by 1%.
Excluding the household products divestiture the quarter growth in the US would
have been +5%. The sales growth was primarily due to Sensodyne toothpaste for
sensitive teeth, Polident denture cleansers, BC Headache Powders, Balmex Diaper
Rash Ointment and our newly introduced product Atridox. Sales of $11.7 million
in Latin America were down by 8% in the quarter mainly due to the devaluation
which took place in Brazil earlier this year and the recessive economies in
Argentina and Colombia, partially offset by exceptionally strong sales growth
in Mexico. If not for the divestiture of Household Products Latin America sales
would have shown an increase of 8% over last year. Sales in Canada of $8.7
million were up by 6% for the quarter led by Polident, Poli-Grip, Sensodyne
and Nytol.
Total International Division sales of $111.0 million in the second
quarter increased by 11% over last year. European sales of $90.1 million led
the growth with a 12% increase fueled by strong sales of Polident and Corega
denture cleansers and Sensodyne and Parodontax toothpastes.
Group revenues were further enhanced by sales from recent acquisitions
such as Strep, Pilca, Agevit and Chlorhexamed. Total Asia/Pacific sales of
$20.9 million for the quarter were flat with last year. Australia and Japan
sales were soft while Korea, Thailand and New Zealand showed improvement.
<PAGE>10
BLOCK DRUG COMPANY, INC. & SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF OPERATING RESULTS AND FINANCIAL CONDITION
Operating Results: (Cont'd)
Interest, dividends and other income of $ 13.7 million decreased by
25.5 % compared to the first six months of the prior year income of $18.4
million. The decrease was primarily due to prior year income which included
gain on the sale of Household products and a reversal of restructuring and
re-engineering reserves.
The cost of goods sold percentage to sales was 30.8 % and 30.4 % in
the first six months of the current and prior year, respectively. The cost of
goods sold for the Americas Division was 32 % for the first six months of the
current year compared to 30.7 % for the first six months of prior year. The
cost of goods sold for International Division was 29.6 % for the first six
months of the current year compared to 30.0 % for the first six months of prior
year. The change in the cost of goods sold was primarily due to changes in
product mix.
Selling, general and administrative expenses represented 62.1% and
64.2 % of sales for the first six months of current year and prior year,
respectively. The major portion is related to advertising and promotional
activities. These expenses consists of major spending programs to meet
significant competition and build brand equities. Selling, general and
administrative expense percentage to sales declined during the current six
months primarily due to exchange gains in Brazil during the first quarter,
partially offset by increased advertising expenses.
Interest expense was slightly higher in the first six months of the
current year compared to first six months of prior year, primarily due to an
increase in the average debt outstanding resulting from additional financing
obtained for product acquisitions.
The Company's foreign exchange exposures derive primarily from the
activities of its foreign subsidiaries and affiliates which sell products to
customers generating accounts receivable both in their own local currency and
in other currencies. Certain subsidiaries, principally manufacturing locations
in the United Kingdom, Ireland and Brazil, also incur significant costs
denominated in currencies other than their functional currency.
Additionally, the Company is exposed to the risks that the results of
operations of its foreign affiliates may translate to lower than expected net
income for inclusion in the Company's consolidated results.
Interest rate cap agreements and foreign currency options are the only
types of derivatives used by the Company for risk management. The costs and
benefits derived from the interest rate caps are taken into income over the
terms of the respective agreements.
The Company purchased additional interest rate caps during this
period to protect against increases in the cost of servicing Euro 100 Million
of Euro denominated variable rate debt. These agreements over a period of five
years, protecting against the 90 day Euribor rate exceeding 4.5% during the
first two years and 5.5% during the next three years. The cost of the
agreements is being paid in quarterly installments over their term and these
costs are taken into expense when paid.
<PAGE>11
BLOCK DRUG COMPANY, INC. & SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF OPERATING RESULTS AND FINANCIAL CONDITION
Operating Results: (Cont'd)
The Company manages its most significant foreign currency exposures,
principally inventory purchases, by purchasing average rate currency options
that protect against the fiscal year average value of each currency declining
more than an acceptable amount from the average for the prior year. Currencies
that are highly correlated to the U.S. dollar and those that are illiquid or
have high interest rates (and therefore hedging cost) are not hedged. However,
certain affiliates in high interest rate environments maintain cash balances in
U.S. Dollars. If the affiliate's functional currency declines against the
dollar, such balances would produce incremental income, thereby offsetting the
declining dollar value of the affiliate's results included in the Company's
net income.
The cost of foreign currency options are expensed over the period to
which they relate and any benefits, to the extent of options deemed effective
hedges, are treated as an adjustment to the related costs of inventory when
purchased.
Consolidated operating income increased 9.6%. Americas income
decreased 5.6% and International income increased 31.2 %. The decrease in the
Americas Division was primarily due to divestiture of Household product brands.
The growth in the International division was primarily due to improved gross
margins along with a reduction in S,G&A as a percentage of sales.
Due to the above factors, income before taxes was 8.8 % of sales during
the six months ended September 30, 1999 as compared to 8.4 % during the six
months ended September 30, 1998.
The effective income tax rates of 26.2% and 25.3 % for the six months
ended September 30, 1999 and 1998, respectively, reflect tax exempt interest
from government securities and income from the lower tax areas of Puerto Rico
and Ireland. The increase in the tax rate was primarily due to increased income
in higher taxed jurisdictions.
It is difficult to predict future exchange rate movement. If exchange
rates would continue at current levels, management does not anticipate any major
material effects on the Company's future financial condition or liquidity.
In February 1997, the Company announced the consolidation of its
manufacturing operations by planning to close six of its twelve production
facilities in various parts of the world over a two year period. The worldwide
manufacturing restructuring and re-engineering program resulted in a pre-tax
charge of $72.5 million ( $55.7 million net of tax), or $2.60 per share after
taxes in fiscal 1997. As of September 30,1999, the Company's remaining
obligation of $8.7 million consists of its contractual obligation to produce a
product for another entity. (See Note 9).
<PAGE>12
BLOCK DRUG COMPANY, INC. & SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF OPERATING RESULTS AND FINANCIAL CONDITION
Operating Results: (Cont'd)
Subsequent to the close of the quarter, the Company sold the remaining
manufacturing facility at a price that is approximately equal to the net
book value of the property. In connection with the sale, the Company will
be relieved of its contractual obligation described above but will incur
training costs and other expenses to move production equipment to an
unrelated party's facility. Management anticipates that this sale should
resolve all remaining contingencies associated with the restructuring reserve.
During the quarter the Company acquired Chlorhexamed, a medicated
mouth wash in Holland. In Latin America, the Company acquired Silidron and
Espasmo Silidron, two anti-gas medicines sold in Brazil. In Korea, the Company
acquired the balance of certain marketing rights to the Parodontax brand
toothpaste. The aggregate amount spent on these acquisitions was $50.6 million.
Goodwill recorded in connection with these acquisitions amounted to $50.0
million.
Subsequent to the close of the quarter, in U.K., the Company acquired
Interdens a professional dental product. In Spain, the Company acquired Marie
Yvonne a depilatory brand. The aggregate amount spent on these acquisitions was
$4.2 million, the majority of which is considered goodwill.
YEAR 2000
As many computer systems and other equipment or processors with
embedded chips (collectively, "Business Systems") use only two digits to
represent the year, they may be unable to process accurately certain data,
before during or after the year 2000. As a result, business and government
entities are at risk for possible miscalculations or systems failures causing
disruption in their business operations. This is commonly know as the year 2000
(Y2K Millennium Bug or Y2K problem). The Y2K problem can arise at any point in
the Company's supply, manufacturing, processing, distribution and financial
chains.
Block Drug Company and each of its operating subsidiaries are in the
process of implementing a Y2K compliance readiness program with the objective
of having all of their significant Business Systems, including those that
affect facilities and manufacturing activities, functioning properly with
respect to the Y2K problem before January 1, 2000. All operating subsidiaries
are in the remediation stage of Y2K readiness.
The first component of the Y2K compliance program is to identify the
internal Business Systems of the Company and its operating subsidiaries that are
susceptible to system failures or processing errors as a result of the Y2K
problem. This effort is substantially complete with all operating subsidiaries
having identified the Business Systems that may require remediation or
replacement and established priorities for repair or replacement.Those Business
Systems considered most critical to continuing operations are being given the
highest priority.
The second component of the Y2K compliance program involves the actual
remediation and replacement of Business Systems. The Company and its operating
subsidiaries are using both internal and external resources to complete this
process. The Business Systems ranked highest in
<PAGE>13
BLOCK DRUG COMPANY, INC. & SUBSIDIARIES
MANAGMENT'S DISCUSSION AND ANALYSIS
OF OPERATING RESULTS AND FINANCIAL CONDITION
YEAR 2000: (Cont'd)
priority have either been remediated, replaced or scheduled for remediation or
replacement. Business Systems previously earmarked for retirement and
replacement without regard to the Y2K problem have been evaluated for early
replacement with Y2K compliant systems or programs or, in the alternative,
remediation. The Company is in the process of implementing Y2K compliant
software/hardware wherever needed in the US as well as fixing or replacing
hardware and software where warranted, with Y2K compliant solutions in our
Affiliates. The Company completed all remediation and replacement of its U.S.
based internal Business Systems in March 1999. The final testing and
certification for Y2K readiness of all mission critical systems have been
completed, and the contingency plans are in the final stages of completion.
As part of the Y2K compliance program, significant service providers,
vendors, suppliers, customers and government entities that are believed to be
critical to business operations after January 1, 2000, ("Key Business Partners")
have been identified and contacted through questionnaires, interviews or on-site
visits to ascertain their stage of Y2K readiness. Where ever we have electronic
or computer to computer communications with Key Partners, we plan to
jointly test these interfaces. In conjunction with this effort, key government
agencies and utilities upon which the Company and its subsidiaries rely are
being approached on a worldwide basis to identify their level of Y2K
preparedness. In many cases these entities, particularly those outside
North America, have a lower level of Y2K readiness.
Because of the vast number of Business Systems used by the Company and
its operating subsidiaries, the significant number of Key Business Partners and
extent of the Company's foreign operations, the Company presently believes that
it may experience some disruption in its business due to the Y2K problem. More
specifically, because of the interdependent nature of Business Systems, the
Company and its operating subsidiaries could be materially adversely affected
if utilities and government entities with which they do business or that provide
essential services are not Y2K ready. The Company currently believes that the
greatest risk of disruption in its businesses exists in certain international
markets. The possible consequences of the Company or Key Business Partners not
being fully Y2K compliant by January 1, 2000 include, among other things,
temporary plant closings, delay in the delivery of products, delay in receipt
of supplies, invoice and collection errors, and inventory and supply
obsolescence. Concurrently, the business and results of operations of the
Company could be materially adversely affected by a temporary inability of the
Company and its operating subsidiaries to conduct their businesses in
the ordinary course for a period of time after January 1, 2000. However, the
Company believes that its Y2K readiness program, including the contingency
planning discussed below, should significantly reduce the adverse effect of
such disruptions.
Concurrently, with the Y2K readiness measures described above, the
Company and its operating subsidiaries have developed contingency plans intended
to mitigate the disruption in business operations that may result from Y2K
problems. Contingency plans include stockpiling raw and packaging materials,
increasing inventory levels, securing alternate sources of supply, adjusting
facility shut-down and start-up schedules and other appropriate measures. Once
developed, contingency plans and related cost estimates will be continually
refined as additional information becomes available.
<PAGE>14
BLOCK DRUG COMPANY, INC. & SUBSIDIARIES
MANAGMENT'S DISCUSSION AND ANALYSIS
OF OPERATING RESULTS AND FINANCIAL CONDITION
YEAR 2000: (Cont'd)
The Company estimates that expenses will reach a total of about $17.5
million to address its Y2K effort as well as other business information
requirements. To date, the Company has spent approximately $16.6 million. These
amounts do not include any costs associated with the implementation of
contingency plans, which are in the process of being completed.
The Company's Y2K compliance program is an ongoing process. Therefore,
the estimates of costs and completion dates for various components of the Y2K
compliance program are subject to change. The Company is, however, making every
effort to ensure that costs are forecasted as accurately as possible and
scheduled completion dates are achieved.
The estimates and conclusions herein contain forward-looking statements
and are based on managements best estimates of future events. The risks to
completing the plan include the availability of resources at specific facilities
and the ability of suppliers to bring their systems into Year 2000 compliance.
Euro Currency Adoption
As result of the European Economic and Monetary Union, a single
currency (the "Euro") will replace the national currencies of many of the
European countries in which the Company conducts business. The conversion rates
between the Euro and the participating nations' currencies were fixed as of
January 1, 1999, with the participating national currencies scheduled
to be removed from circulation between January 1, and June 30, 2002, and
replaced by Euro notes and coinage. During the transition period from
January 1, 1999 through December 31, 2001, public and private entities as well
as individuals may pay for goods and services using either checks, drafts, or
wire transfers denominated in Euros or the participating country's national
currency. Euro conversion did not have a material negative impact on operations
in fiscal 2000. All affiliates can operate within the Euro market.
We are currently upgrading our computer systems so that we can operate
more efficiently within the Euro market in fiscal 2000.
<PAGE>15
Financial Condition
Cash and cash equivalents increased for the six month period ended
September 30,1999 to $61.9 million from $48.4 million at year-end
March 31, 1999. The increases resulted primarily from an increase in short-term
debt and proceeds from the divestiture of Lava soap and the sale of Canadian
property partially offset by payments made to acquire new products and by
an increase in inventory.
In the prior year six months cash and cash equivalents decreased to
$28.1 million from $37.3 million at year-end March 31, 1998. The decrease
resulted primarily from decreases in accounts payable and in short-term debt
partially offset by the issuance of long term debt and proceeds from the sale
of assets.
Quantitative and Qualitative Disclosures about Market Risk
Refer to the market risk and sensitivity analysis in the Management's
Discussion and Analysis section of the Company's 1999 Annual Report and
Form 10-K.
New Accounting Standards
In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivatives
and Hedging Activities," which establishes accounting and reporting standards
for derivative instruments, including certain derivative instruments embedded
in other contracts (collectively referred to as derivatives) and for hedging
activities. In June 1999, the FASB issued SFAS No. 137, "Accounting For
Derivatives and Hedging Activities - Deferral of the Effective Date of SFAS
No. 133," which makes SFAS No. 133 effective for all fiscal quarters of fiscal
years beginning after June 15, 2000. The Company is currently evaluating the
impact of the new statement on it's financial position, results of operations
and disclosures for fiscal 2002.
<PAGE>16
PART II. OTHER INFORMATION
Item 1. Legal Proceedings:
The company is involved in various routine ligation incidental to its
continuing and discontinued operations. While the significance of these
matters cannot be fully assessed at this time, management, on advice of
counsel, does not believe that any liability that may arise from these
proceedings will have a material adverse impact on the Company's
consolidated financial position, results of operations or liquidity.
Item 6. Exhibits and Reports on Form 8K
(a) The exhibits filed as part of this report are listed below:
Exhibit No. Description
27 Financial Data Schedule
(b) Reports on Form 8K
There were no reports on Form 8K for the three months ended
September 30, 1999.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BLOCK DRUG COMPANY, INC.
(Registrant)
November 15, 1999 PETER ANDERSON
DATE Peter Anderson
Senior Vice President &
Chief Financial Officer
<PAGE>17
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> MAR-31-2000
<PERIOD-START> APR-01-1999
<PERIOD-END> SEP-30-1999
<CASH> 61866
<SECURITIES> 21763
<RECEIVABLES> 155558
<ALLOWANCES> 4670
<INVENTORY> 147373
<CURRENT-ASSETS> 429372
<PP&E> 383166
<DEPRECIATION> 138491
<TOTAL-ASSETS> 1201779
<CURRENT-LIABILITIES> 392005
<BONDS> 0
0
0
<COMMON> 2289
<OTHER-SE> 674940
<TOTAL-LIABILITY-AND-EQUITY> 1201779
<SALES> 415763
<TOTAL-REVENUES> 429458
<CGS> 127876
<TOTAL-COSTS> 127876
<OTHER-EXPENSES> 258121
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 6842
<INCOME-PRETAX> 36619
<INCOME-TAX> 9594
<INCOME-CONTINUING> 27025
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 27025
<EPS-BASIC> 1.18
<EPS-DILUTED> 1.18
</TABLE>
